Clinical link between MHC class II haplotype and interferon-beta (IFN-β) immunogenicity
MDFS Barbosa, J Vielmetter, S Chu, DD Smith… - Clinical …, 2006 - Elsevier
Interferon-beta (IFN-β) is currently the first-line therapy for the treatment of multiple sclerosis
(MS). However, a significant percentage of MS patients develop anti-IFN-β antibodies, which
can reduce the efficacy of the drug. We describe an association between a common MHC
class II allele (DRB1* 0701), present in 23% of the patients studied, and the anti-IFN-β
antibody response. We identified IFN-β epitopes using a peptide-binding assay with B cell
lines expressing this allele. Moreover, epitope-specific activation responses obtained with …
(MS). However, a significant percentage of MS patients develop anti-IFN-β antibodies, which
can reduce the efficacy of the drug. We describe an association between a common MHC
class II allele (DRB1* 0701), present in 23% of the patients studied, and the anti-IFN-β
antibody response. We identified IFN-β epitopes using a peptide-binding assay with B cell
lines expressing this allele. Moreover, epitope-specific activation responses obtained with …
